Treatment for Perimenopausal Cognitive Symptoms and Anxiety Without Vasomotor Symptoms
For perimenopausal women presenting with cognitive symptoms and anxiety but without vasomotor symptoms, hormone therapy (estrogen alone or estrogen plus progestogen) should be considered as first-line treatment, as perimenopausal depression and cognitive symptoms have a hormonal etiology and may not respond adequately to conventional antidepressants alone 1.
Rationale and Treatment Algorithm
Primary Consideration: Hormonal Etiology
Perimenopausal cognitive and mood symptoms represent a distinct syndrome driven by fluctuating gonadal hormones, not simply a gradual hormone deficiency 1. The neurochemical changes from hormonal fluctuations affect mood, cognition, and behavior in susceptible women, with psychological symptoms often appearing as the earliest signs of perimenopause—affecting up to 80% of women 1.
Key clinical point: Even without vasomotor symptoms, the underlying hormonal disruption can cause significant cognitive and anxiety symptoms. The absence of hot flashes does not exclude hormonal treatment as appropriate therapy.
Treatment Approach
Step 1: Establish Diagnosis and Baseline Risk
- Confirm perimenopausal status through menstrual history patterns and, when indicated, replicate FSH and estradiol measurements 2
- Assess cardiovascular disease risk, as this determines treatment selection 2
- Use diagnostic tools like the Meno-D scale to identify perimenopausal depression 1
Step 2: Initiate Menopausal Hormone Therapy (if no contraindications)
For women without contraindications or excess cardiovascular/breast cancer risks 2:
- Women without uterus: Estrogen therapy (ET) alone
- Women with uterus: Estrogen plus progestogen therapy (EPT)
Cardiovascular risk stratification matters:
- High CVD risk: Consider nonhormonal therapies first (see Step 3) 2
- Moderate CVD risk: Use transdermal estradiol as first-line, combined with micronized progesterone for women with uterus, as these have fewer metabolic effects 2
- Low CVD risk: Standard MHT preparations are appropriate 2
Critical caveat: Use only FDA-approved MHT preparations; avoid custom-compounded hormones 2. Employ shared decision-making regarding formulation, dose, and route 2.
Step 3: Nonhormonal Alternatives (if MHT contraindicated or declined)
When hormone therapy is inappropriate or unwanted, evidence supports:
SSRIs/SNRIs:
- Venlafaxine 75 mg or escitalopram 10-20 mg showed comparable efficacy to estradiol for symptom relief in perimenopausal women 3
- Paroxetine 7.5 mg daily improved symptoms without weight gain or sexual dysfunction 3
- Important warning: Avoid fluoxetine and paroxetine in breast cancer patients on tamoxifen due to drug interactions 3
Gabapentin:
- 900-1800 mg daily demonstrated efficacy over placebo for symptom relief and improved sleep 3
- Side effects include dizziness (12.7%), headache (9.3%), and somnolence (6.0%), which typically improve after several weeks 3
Cognitive Behavioral Therapy:
- CBT showed significant improvements in stress, anxiety, somatic and psychological symptoms, and sleep compared to psychoeducation alone 4
- Combination approaches (pharmacotherapy plus psychotherapy) demonstrated superior outcomes across multiple psychological and endocrine measures compared to single-modality treatment 5
Adjunctive Interventions
Lifestyle and supportive measures should be addressed concurrently 2:
- Bone health optimization
- Cardiovascular risk management
- Smoking cessation
- Alcohol use assessment
- Cancer screening
Psychotherapy integration: Trauma-informed psychotherapy should be considered as part of individualized treatment, particularly given the distinct hormonal etiology of perimenopausal depression 1.
Evidence Considerations and Nuances
The guideline evidence 2, 3 focuses primarily on vasomotor symptoms, but recent research 1 emphasizes that perimenopausal depression and cognitive symptoms represent a distinct syndrome that is "often not responsive to conventional antidepressant management" alone. This creates a clinical gap where hormone therapy may be appropriate even without classic hot flashes.
Divergent evidence note: While SSRIs/SNRIs showed comparable efficacy to estradiol in trials 3, these studies enrolled women with vasomotor symptoms. The 2026 research 1 specifically identifies perimenopausal depression as having a hormonal etiology requiring tailored treatment including MHT.
Monitoring and Safety
- Review the decision to continue MHT at least annually 2
- Target the shortest duration consistent with treatment goals 2
- Inform patients about potential increased breast cancer risk with EPT and ensure age-appropriate screening 2
- Evaluate any persistent unscheduled bleeding to rule out endometrial pathology 2
Common pitfall: Assuming that absence of vasomotor symptoms means hormone therapy is inappropriate. Cognitive and mood symptoms can be the predominant or sole manifestation of perimenopausal hormonal changes and may warrant hormonal treatment.